Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Imprinted Binary Colloidal Crystals Support Growth and Stemness of Mouse Embryonic Stem Cells
Babaie, Ali , Wang, Peng‐Yuan , Abedi, Ali , Uddin, Md Hemayet , Joseph, Shanthi, Sümer, Hüseyin , Uddin, Hemayet , Thissen, Helmut , Kingshott, Peter , Abedi, Ali

Mayo Clinic

ACS Biomaterials Science & Engineering | December 8, 2025 | Volume: 12 | Issue: 4 | Pages: 2156-2172

10.1021/acsbiomaterials.5c01187 | PMID 41358614 Get It

Risk Models for Adverse Events in Microsurgery for Intracranial Unruptured Aneurysms
Adamides, Alexios A. , Başkaya, Mustafa K. , Ieva, Antonio Di , Lawton, Michael T. , Pinna, Giampietro, Podlesek, Dino , Radovanovic, Ivan, Rohde, Veit, Stroh-Holly, Nico , Sturiale, Carmelo Lucio, Investigators, for the PRAEMIUM, Oushy, Soliman , Bervini, David , Fierstra, Jorn , Staartjes, Victor E , Oushy, Soliman H , Bervini, David , Staartjes, Victor E. , Anania, Pasquale , Beneš, Vladimír , Dehdashti, Amir R. , Ferroli, Paolo , Jakola, Asgeir Store , Lanzino, Giuseppe , Petr, Ondra , Petutschnigg, Thomas , Rohde, Veit , Sturiale, Carmelo Lucio , Wang, Anthony , Regli, Luca , Esposito, Giuseppe, Investigators, for the PRAEMIUM, Goldberg, Johannes

Mayo Clinic

Neurosurgery | December 5, 2025 | Volume: 99 | Issue: 2 | Pages: 452-460

10.1227/neu.0000000000003867 | PMID 41358665 Get It

BACKGROUND AND OBJECTIVES: Preventive treatment of unruptured intracranial aneurysms (UIAs) requires assessment of treatment risks vs expected benefit. Although established scores exist to estimate rupture and growth risk, currently, no externally validated tools exist to estimate the risks of microsurgical treatment of UIAs. Clinical prediction models based on machine learning enable generation of personalized risk estimates for each individual patient based on their specific patient and aneurysm characteristics. METHODS: Using data from 20 international centers from the prediction of adverse events after microsurgery for intracranial unruptured aneurysms study on patients treated microsurgically for UIAs, we developed and externally validated clinical prediction models for 3 outcomes measured at hospital discharge: poor neurological outcome (modified Rankin Score ≥3), new sensorimotor neurological deficits, and all-cause adverse events (Clavien-Dindo Grade ≥1). RESULTS: A total of 3705 patients were included. Data from 13 centers (2881, 78%) were used for model development. Fully trained models were evaluated on 824 patients (22%) from 7 additional centers. Average age was 56 ± 12 years, and 1049 (28%) were male. At discharge, poor neurological outcome was seen in 514 patients (14%). New sensorimotor deficits were observed in 534 patients (14%), and 894 patients (24%) experienced adverse events until discharge. At external validation, prediction of poor neurological outcome was achieved with good calibration and an area under the curve (AUC) = 0.70 (95% CI: 0.63-0.75). Similarly, new neurological deficits were predicted with good calibration and with an AUC = 0.69 (95% CI: 0.63-0.74). Prediction of all-cause adverse events only achieved an AUC = 0.59 (95% CI: 0.55-0.64) with fair calibration. The prediction model was integrated into a web application accessible at https://neurosurgery.shinyapps.io/PRAEMIUM/. CONCLUSION: The developed models for prediction of poor neurological outcome and new sensorimotor neurological deficits at discharge exhibit good calibration and fair discrimination based on a multinational external validation, indicating that the predicted probabilities correspond well to real-world risks and may thus be clinically useful in more objectively estimating the risk of microsurgical treatment.
Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation
Shumway, Dean A. , Corbin, Kimberly S. , Farah, Magdoleen H. , Fleti, Farah, Hasan, Bashar , Firwana, Mohammed , Saadi, Samer , Nayfeh, Tarek , Hegazi, Moustafa , Waddle, Mark R. , Amundson, A., Vallow, Laura A., Mutter, Robert W. , Shiraishi, Satomi , Farah, Magdoleen H , Fleti, Farah , Hasan, Bashar , Firwana, Mohammed M , Saadi, Samer , Nayfeh, Tarek , Hegazi, Moustafa , Waddle, Mark R , Amundson, Adam C., Hieken, Tina J , Park, Sean S , Mutter, Robert W , Murad, M Hassan , Shumway, Dean A , Shiraishi, Satomi , Vargas, Carlos E, Oladeru, Oluwadamilola T. , Hieken, Tina J. , Park, Sean S. , Murad, M. Hassan , Wang, Zhen

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 5, 2025 | Volume: 118 | Issue: 4 | Pages: 691-698

10.1093/jnci/djaf346 | PMID 41352976 Get It

Abstract Background Partial breast irradiation (PBI) is an effective treatment for early-stage breast cancer. However, evidence comparing different PBI modalities is limited. Methods This trial emulation uses electronic health records from a multi-state large tertiary health system. Three PBI modalities were compared: proton radiation therapy, photon radiation therapy, and applicator-based brachytherapy. Inverse probability weighting (IPW) was used to balance confounders. The primary outcome was ipsilateral breast recurrence (IBR). Results Between 2013 and 2023, 1041 women with early-stage breast cancer were treated with PBI. Of these, 1026 patients were included in the analyses. The median age was 66 years; 22.51% had ductal carcinoma in situ (DCIS), and 97.56% were estrogen receptor positive. With median follow-up of 38.2 months, the rate of IBR in the overall group was 3.05% (95% confidence interval [CI] = 1.99% to 4.65%) at 3 years. After IPW, compared with photon PBI, the hazard ratio for IBR for proton PBI was 2.11 (95% CI = 0.70 to 6.33) and for brachytherapy, 3.86 (95% CI = 1.39 to 10.69). Compared with proton PBI, the hazard ratio for IBR for brachytherapy was 1.83 (95% CI = 0.88 to 3.81). IBR risk was similar across PBI modalities for patients with tumor size ≤ 10 mm and in patients treated for DCIS. Among patients with tumor size >10 mm, the hazard ratio for IBR for brachytherapy was 7.64 (95% CI = 1.64 to 35.58) and 3.59 (95% CI = 1.22 to 10.56) relative to photons and protons, respectively. Conclusion PBI with applicator-based brachytherapy was associated with higher IBR than photon or proton PBI in patients with tumor size > 10 mm, suggesting the need for more careful PBI patient selection for this modality.
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis
Kong, Xue, Xu‐Monette, Zijun Y. , Xu, Zhenming , Zhao, Xiaoxian , Nunns, Harry , Visco, Carlo , Tzankov, Alexandar , Dybkær, Karen , Yao, Shuna , Wu, Dehong , Wang, Chang , Pan, Zenggang , Parsons, Benjamin M. , Chiu, April , Tam, Wayne , Zhan, Fenghuang , Bernal‐Mizrachi, Leon , Zu, Youli , Zhang, Shanxiang , Chen, Weina , Au, Qingyan , Merchant, Akil , Bhagat, Govind , Young, Ken H. , Visco, Carlo , Dybkaer, Karen , Wang, Chang , Xu, Alexander M , Pan, Zenggang , Parsons, Benjamin M , Chiu, April , Zhan, Fenghuang , Møller, Michael Boe , Chen, Weina , Merchant, Akil , Bhagat, Govind , Li, Yong , Young, Ken H , Tzankov, Alexandar , Zu, Youli , Xu-Monette, Zijun Y , Hsi, Eric D. , Yan, Hui Min , Au, Kelly, Xu, Alexander M. , Montes‐Moreno, Santiago , Møller, Michael , Li, Yong

Mayo Clinic

Blood Advances | December 5, 2025 | Volume: 10 | Issue: 5 | Pages: 1756-1772

10.1182/bloodadvances.2025017643 | PMID 41346287 Get It

Abstract Pyroptosis is a form of programmed cell death characterized by the cleavage of the gasdermin (GSDM) family proteins that form pores in the plasma membrane, cell rupture, and the release of proinflammatory cytokines. In this study, we performed immunohistochemistry for cleaved gasdermin D (GSDMD), gasdermin E (GSDME) N-terminus, and gasdermin C (GSDMC) in 2 different cohorts of diffuse large B-cell lymphoma (DLBCL) and analyzed the impact of GSDM expression on prognosis and immunity. The results showed frequent cleaved GSDMD (N-terminal) expression. Only cytoplasmic GSDMD N-terminal expression correlated with significantly better patient survival in the 2 cohorts. In contrast, GSDME was mainly expressed in the vascular endothelium, and correlated with significantly adverse prognostic effect. Correlating with the multiplex fluorescent immunohistochemistry results, we found that cytoplasmic GSDMD N-terminal expression was associated with increased CD38+ (activated) M1 macrophages in both cohorts, cognate interactions between live DLBCL cells and activated M1 macrophages (and T cells), and lower PD-1/PD-L1 expression in the analyzed cases. In contrast, T-cell pyroptosis, lymphoma cell-resistance to cell death, and phagocytosis by M2 macrophages were observed in tissues with predominantly nuclear GSDMD N-terminal expression. Bulk gene expression profiling and deconvolution analysis revealed associations of cytoplasmic GSDMD N-terminal expression with downregulation of “Don’t eat me”–signaling genes, upregulation of many RNA genes, decreased frequency of “inflammatory” lymphoma microenvironment subtype, increased frequencies of prognostically favorable cell states and ecotypes, and decreased frequency of T-cell exhaustion state. In summary, this study showed distinct cellular and subcellular patterns of 3 GSDM proteins and their associated immune response phenotypes and prognostic effects, with implications for novel therapeutic strategies for B-cell lymphoma.
Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma
Tan, Melinda Si Yun , Corraes, Andre De Menezes Silva , Wang, Panwen , Wu, Chen , Shao, Zuoyi , Regan, Kevin M., Ma, Audrey, Khurana, Arushi , Hampel, Paul J. , Johnston, Patrick B. , Ansell, Stephen M. , Lin, Yi , Mondello, Patrizia , Turner, Jacqueline A. , Bennani, N. Nora , Wang, Yucai , Paludo, Jonas , Kenderian, Saad S. , Durani, Urshila , Villasboas, José C. , Zeng, Hu , Dong, Haidong , Li, Ying

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5894-5894

10.1182/blood-2025-5894 Get It

Abstract Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable response rates in relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. However, durable remissions occur in only 40% of treated patients, highlighting mechanisms of therapeutic resistance and immune escape. While cytotoxicity is principally executed by CAR T-cells, monocytes shape CAR-T cell efficacy and orchestrate cytokine-driven immunity. In this study, we defined distinct metabolic profiles of T-cell and monocyte subsets based on clinical response. Single-cell RNA sequencing (scRNA-seq) and T-cell receptor sequencing (scTCR-seq) were performed on peripheral blood mononuclear cells at three timepoints: before lymphodepletion (BL), at peak CAR-T expansion (PK), and one-month post-infusion (M1). Data were processed with CellRanger v7.0.1 and analyzed with the immunopipe pipeline (Wang et al., 2025). Seurat v4.3.0 was utilized for unsupervised hierarchical clustering analysis; subsets identified included classical monocytes (CM), intermediate monocytes (IM), non-classical monocytes (NM), and monocytic myeloid derived suppressor cells (mMDSC). Metabolic profiles were compared across patients achieving ≥6-month complete remission (CR, n=16), primary refractory disease (PD1, n=4), or relapsed after a prior response (PD2, n=12). A total of 107035 T cells and 129981 monocytes from 77 serial samples in 32 patients were analyzed. CR patients had a higher T-cell:monocyte ratio than PD1/PD2 at all time points, especially at BL and PK (BL 1.2 vs 0.4, p=0.011; PK 1.3 vs 0.3, p=0.027). Clinical responses were compared with metabolic pathway analysis and identified oxidative phosphorylation (OXPHOS) as the dominant pathway. OXPHOS was consistently enriched in PD cohorts across T-cell subsets, particularly in PD1 vs CR at BL (mucosal-associated invariant T-cell (MAIT) and T peripheral memory (Tpm)), and at PK (CD4/CD8 memory precursor effector cells (MPEC) and activated MPECs (MPECa), CD4 T-helper 1 proliferating (Th1p), CD4 Th2 activated (Th2a), regulatory T-cell (Treg), CD8 naive senescent (CD8NS), CD8 T effector memory (Tem) tumor recirculating (TR), CD8 Tpm, CD8 T resident memory (Trm) TR and MAIT Tpm). By M1, OXPHOS enrichment in CD4/CD8MPECa, CD4Th2a, CD8NS, CD8TemTR reversed, now predominant in CR although CD8Tpm and CD8TrmTR remained enriched in PD1. In the monocyte subsets at BL, PD2 showed OXPHOS enrichment in CD163+ monocytes (mono), IM IL1, mMDSC SIRPA, mMDSC TGFβ, and CM IL6 subsets compared to PD1 and CR, while PD1 showed OXPHOS enrichment in IM CD38, CM TGFβ, and mMDSC HIF1A vs CR and PD2. This persisted at PK. By M1, the pattern reversed and mirrored that of T-cells, with CR patients showing OXPHOS enrichment in CD163+mono, CM IL6, CM TGFβ, IM CD38, mMDSC HIF1A, mMDSC SIRPA and mMDSC TGFβ, and additionally in CM EMT, CM p53, NM, NM CD36 vs PD1/PD2. Glycolysis/gluconeogenesis (GLY) was also enriched across subsets. In T-cells, PD1 vs CR showed GLY enrichment in CD4Th2a, CD8Tpm, CD8Tpm proliferating and MAIT Tpm at PK. In monocytes, GLY was enriched in PD1/2 vs CR at BL (CD163+mono, CM IL6) and PK (CD163+mono, IM CD18, mMDSC SIRPA). By M1, GLY metabolism was enriched in CR vs PD1/PD2 in CD163+mono, CM IL6, mMDSC SIRPA. Additional GLY enriched subsets at CR vs PD1 included CM, CM p53, EMT, IM CD38, IM IL1, mMDSC HIF1A, NM, NM CD36. Inositol phosphate metabolism (IP) was predominantly enriched in PD2 vs CR at BL (CD8NS, CD8Tcm, CD8Tpm activated), PK (CD4Th2, CD8NS, CD8Tem TR, CD8Tpm proliferating, γδT Tem) and M1 (CD4/CD8 MPECa, CD4 Th1/Th2, CD8NS, CD8Tpm, CD8 Tpm proliferating, Treg and MAIT Tpm). Notably, Treg was the only T-cell subset enriched for IP at PK in CR vs PD1/PD2. Additionally, the TCA cycle was enriched in PD1 Tregs and Th2 cells at BL and PK vs CR/PD2. A higher T-cell:monocyte ratio in CR vs PD1/PD2 supports prior evidence that elevated pre-lymphodepletion lymphocyte:monocyte ratios predict better outcomes. We identified distinct metabolic signatures in T-cells and monocytes between CR and PD1/PD2. OXPHOS enrichment in T-cells and monocytes at M1 in CR patients may reflect oxidative programming as a hallmark of sustained anti-tumor immunity. Conversely, GLY enrichment in PD1 T-cells at PK may reflect short-lived effector states lacking persistence. Overall, these findings highlight metabolic profiling as a promising predictive biomarker and therapeutic programming target to enhance CAR T-cell outcomes.
Contemporary survival trends in patients with adult T-cell leukemia/lymphoma (ATLL) in the United States: Insights from the national cancer database
Toumeh, Nadia , Marar, Rosalyn, Day, Jonathan R , Yu, Tao , Zhou, Jihao , Hwang, Steven R. , Wang, Yucai , Godby, Richard

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1871-1871

10.1182/blood-2025-1871 Get It

Abstract Introduction: Adult T-cell leukemia/lymphoma (ATLL) is a rare blood disorder associated with human T-cell leukemia virus type 1 (HTLV-1) infection. It is generally categorized into four subtypes: smoldering, chronic, lymphoma, and acute. Given the heterogeneity of these subtypes, there is a significant difference in outcomes. Robust and contemporary epidemiological data are lacking for this rare disorder. We present a retrospective cohort study of patients with ATLL, utilizing the National Cancer Database (NCDB) to better characterize the epidemiology and survival trends in the United States. Methods: This is a retrospective cohort study using the NCDB to identify ATLL cases diagnosed from 2004-2020. Descriptive statistics summarized baseline characteristics, while chi-square tests assessed group differences. Overall survival (OS) was estimated using Kaplan-Meier analysis and compared using log-rank tests. Multivariable Cox proportional hazards models identified independent prognostic factors (p < 0.05 considered significant). Results: A total of 635 patients were identified with ATLL, including 344 (54%) males and 291 (46%) females, with a median age at diagnosis of 59 years (range: 19-90). Most patients came from the Middle Atlantic (NY, NJ, PA) region (33%), followed by the South Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, WV) region (20%) and the East North Central (IL, IN, MI, OH, WI) region (8%). Of the 635 patients, 335 (52%) were Black, 247 (39%) White, and 26 (4%) Asian. Sixty-five (10%) patients were of Hispanic origin. Over half of patients with ATLL (54%) had a median income below $46,000. International Prognostic Index (IPI) score was only available for 16 patients: three (19%) patients were in the high-risk group, 7 (43%) in the high-intermediate group, and 6 (37.5%) in the low-intermediate group. Treatment groups included 357 (56%) patients treated with chemotherapy and 29 (4.5%) who received radiation therapy. Thirty-three (5%) patients underwent hematopoietic stem cell transplant (HSCT), including 27 autologous and 16 allogeneic transplants. The median survival time in the cohort was 9 months (95% CI 7.3-10.7). One-year OS rate in the cohort was 43%, while 2-year and 5-year OS rates were 31% and 23.5%, respectively. Patients over the age of 65 had a significantly shorter median OS than those under 65 (4 vs. 11 months, p=0.001) and were significantly less likely to undergo HSCT (p< 0.001). Black patients had significantly shorter median OS compared to White patients (7.8 months vs 13.3 months, p=0.014), despite similar treatment rates with chemotherapy and HSCT. Median OS appeared to improve over time, from 8 months in patients diagnosed between 2004-2009 to 10 months for those diagnosed between 2016-2020, although this was not statistically significant (p=0.145). Treatment with allogeneic HSCT was associated with significantly prolonged median survival, compared to those who did not receive transplant (50 months vs. 7 months, p<0.05). Additionally, receiving chemotherapy and/or radiation compared to not receiving treatment was also associated with significantly prolonged median survival (p<0.05). Patients treated in the Middle Atlantic region had a median survival of 8.8 months, compared to 23.2 months in the West South Central (AR, LA, OK, TX) region (p< 0.001). Increased education and income levels were not significantly associated with improved survival. There were no significant differences in survival between males and females. Conclusions: We provide contemporary estimates on the epidemiology of ATLL. Factors associated with improved prognosis included undergoing HSCT, radiation, or chemotherapy. We report that increased age and Black race are negative prognostic factors. Regional differences in incidence and survival persist in the US. Our study findings underscore the need for increasing access to treatment, including HSCT for those who are good candidates. Additionally, there remains work to be done to address racial disparities in the care of patients with ATLL.
Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma
Smith, Stephen D. , Giri, Sharmila, Tatoian, Emily Tamar, Grossfeld, Trenton, Lynch, Ryan C. , Nowakowski, Grzegorz S. , Sundaram, Suchitra , Ness, Andy , Wang, Yucai , Pang, Yifan , Gopal, Ajay K. , Warren, Edus Houston , Park, Steven

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3575-3575

10.1182/blood-2025-3575 Get It

Abstract Introduction: First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. Multitargeted combinations, including optimized chemotherapy with novel agents targeted to MCL, may best address the biologic heterogeneity of this disease. Building on prior experience using modified VR-CAP and R-cytarabine, we enhanced this regimen by adding acalabrutinib while reducing cytarabine, aiming for improved efficacy and safety without impeding stem cell collection. To evaluate this regimen, we conducted a phase 2 multicenter trial at four centers in the Academic and Community Cancer Research United (ACCRU) network. Methods: CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. Eligible patients (pts) were at least 18 years old with adequate organ function, measurable disease, no CNS involvement; and were ASCT-eligible per investigator. VR-CAP (cycles 1, 3, and 5) employed bortezomib 1.3 mg/m² subcutaneously days 1,8, and 15; rituximab 375 mg/m² day 1; cyclophosphamide 750 mg/m² day 1; doxorubicin 50 mg/m2 day 1; and prednisone 100 mg PO days 1-5. Cycles 2,4, and 6 used outpatient rituximab with cytarabine at 3 g/m² x 2 daily doses in the first 5 pts, after which the dose was reduced to 2 gm/m2 x 2 daily doses due to thrombocytopenia. Acalabrutinib 100 mg p.o. twice daily was given continuously but held for grade 4 thrombocytopenia or clinically significant toxicity. Growth factors and prophylactic antimicrobials were required. Responses were assessed after six cycles using FDG PET/CT, bone marrow aspirate/biopsy (BM Bx), and endoscopy when indicated (Lugano 2014). The primary endpoint was complete metabolic response (CMR) rate at end of treatment (EOT). Secondary endpoints included safety, feasibility of stem cell collection, proportion proceeding to ASCT, and progression-free (PFS) and overall survival (OS). Peripheral blood measurable residual disease (MRD) was evaluated using the ClonoSEQ assay (Adaptive Biotechnologies). A Simon two-stage design was used, targeting a CMR rate ≥ 70% versus a null rate of 50%, with a total sample size of 39 evaluable pts. Results: 41 pts were accrued from October 2021 through May 2025, 37 of whom completed all 6 cycles and are evaluable for response; two are still on therapy, and two discontinued therapy early for toxicity. Median age was 63 years (range 41-73), 22% were female, and 85% were White. MIPI risk groups were low (44%), intermediate (39%), and high (17%), and Ki-67 was ≥ 30% in 54% of pts. Three pts (7%) had known TP53 mutations by sequencing. At EOT, the CMR rate was 85.3% among all pts (35/41; 95% CI 67.9%-92.9%), or 94.5% among evaluable pts (35/37). BM Bx was performed in 31 pts at EOT, 30 of which (96.8%) were negative for MCL. Undetectable peripheral blood MRD using a 10^6 threshold (uMRD6) was achieved at EOT in 78.1% (25/32) of tested pts, and 93.8% (30/32) achieved uMRD5. Nine of 41 pts underwent ASCT; no patient failed stem cell collection. Maintenance therapy was not protocol-defined but included rituximab in 91.9% of pts and a BTK inhibitor in 21.6% of pts. With a median follow-up of 16.7 months, PFS and OS rates at 18 months were 76.7% (95% CI: 60.7%-96.9%) and 95.5% (95% CI: 87.1%-100%). Toxicities were primarily hematologic. Grade 3+ toxicities included thrombocytopenia (66.6%), neutropenia (28.2%), and anemia (25.6%). Grade 3+ febrile neutropenia was observed in 10.2% of pts. Peripheral neuropathy was seen in 20.5% of pts and all grade 1-2. Bleeding events included purpura in 2 pts (5.2%) and epistaxis in 1 patient (2.6%). One case of atrial fibrillation was observed. Eighteen pts required temporary dose hold of acalabrutinib for toxicity (mainly thrombocytopenia), and 2 had acalabrutinib dose reductions. Serious adverse events occurred in 6 pts, and no treatment-related deaths occurred. Conclusions: CARiBOU is an efficient, highly effective outpatient regimen for 1st line MCL, employing intermediate dose cytarabine with continuous acalabrutinib. With supportive care and platelet monitoring, this approach safely yielded high rates of CMR and uMRD6, supporting multitargeted induction therapy for appropriate pts with untreated MCL.
Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)
Hampel, Paul J. , Leis, José F., Koehler, Amber B. , Bailen, Rachel, Coddington, Catherine, Behnken, Amy, Schwager, Susan M., Hanson, Curtis A. , Mendoza, Cinthya, Rabe, Kari G. , Maurer, Matthew J. , Wang, Yucai , Kenderian, Saad S. , Muchtar, Eli , Roeker, Lindsey E. , Tsang, Mazie , Hilal, Talal , Parrondo, Ricardo D , Coddington, Catherine, Braggio, Esteban , Shi, Min , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5667-5667

10.1182/blood-2025-5667 Get It

Abstract BACKGROUND Early disease progression within 24 months following chemoimmunotherapy (CIT) is an established adverse prognostic factor for overall survival (OS) in patients (pts) with indolent non-Hodgkin lymphomas. Initially reported in pts with follicular lymphoma, progression of disease (PD) within 24 months in pts with CLL treated with CIT (occurring in ~1-out-of-4 pts) is also associated with inferior OS. The prognostic utility of early event status in pts with CLL treated with targeted therapies is unknown. Recently, we reported worse than expected outcomes with BCL2 inhibitor (BCL2i) treatments in an international cohort of pts with covalent BTK inhibitor (BTKi)-resistant, CIT-naïve CLL. We hypothesize that early disease progression on first-line (1L) targeted agent treatment will identify additional pts with high-risk disease beyond conventional prognostics in the current era. METHODS We identified pts in the Mayo Clinic CLL Database with the following 1L treatments a) BTKi (+/- anti-CD20 monoclonal antibody [CD20mAb]); b) BCL2i + CD20mAb; c) BTKi + BCL2i +/- CD20mAb. PD was defined by a) new or progressive lymphadenopathy or splenomegaly; and/or b) ≥ 50% increase from nadir absolute lymphocyte count (ALC) with persistent (>2 months), and otherwise unexplained ALC ≥ 10x109/L; and/or c) Richter transformation. Logistic regression model evaluated association between clinical factors and POD36 status. OS in pts with PD within 36 months of 1L start (POD36) was evaluated and compared to those without early PD (non-POD36) with analyses: a) starting from time of PD (POD36) and starting from 3 years after 1L initiation (non-POD36); and b) Kaplan-Meier landmark analysis amongst pts alive 3 years post 1L initiation. Cox regression analyses compared a) OS from POD36 by groups and b) OS from 1L treatment with POD36 as a time-dependent covariate. RESULTS A total of 787 pts with CLL initiated 1L targeted therapy (n=538 [68%] BTKi +/- CD20mAb; n=151 [19%] BCL2i + CD20mAb; n=98 [13%] BTKi + BCL2i +/- CD20mAb. The median age at 1L start was 67 years (range 26-92 years), and 67% of pts were male. Among pts with complete CLL-IPI data (n=519), 44% and 15% had high- and very high-risk CLL-IPI risk scores, respectively. Specific pre-1L treatment disease characteristics included TP53 disruption (del17p or TP53 mutation) in 120/639 (19%), del11q in 103/634 (16%), unmutated IGHV in 406/591 (69%), complex karyotype (≥3 clonal structural or numerical abnormalities on karyotype) in 70/273 (26%), and positive CD49d expression in 229/449 (46%). The median pre-treatment beta-2-microglobulin level was 3.3 mcg/mL (range 1.2-24.4 mcg/mL). The median follow-up from 1L start was 50 months (95% CI 46-54 months). 496 pts met criteria for defining POD36 status; 72 (15%) had PD, and 424 did not. TP53 disruption (OR 2.9; 95% CI 1.5-5.7, P=0.001) was associated with POD36 on univariate analysis; complex karyotype, unmutated IGHV status, elevated serum lactate dehydrogenase level, age, sex, and inclusion of CD20mAb were not associated with POD36 status. Median OS from the time of determination of POD36 status was not reached. OS was significantly shorter after POD36 compared to non-POD36 pts (HR 3.5; 95%CI 2.1-6.0, P<0.0001), with 4-year OS estimates of 65% and 88%, respectively. When assessed by landmark analysis at the 3-year timepoint following 1L start (n=50 POD36), OS was also shorter in pts with POD36 compared to non-POD36 pts (HR 3.5; 95%CI 1.8-6.8, P=0.0002). In the overall cohort (n=787), when evaluating OS from 1L treatment with POD36 as a time-dependent covariate, POD36 status was associated with an increased risk of death (HR 4.3; 95% CI 2.6-7.1, P<0.0001) on univariable analysis; and remained an independent marker of shorter OS in multivariable analyses after adjusting for age, sex, TP53 disruption status, and IGHV status (HR 4.2; 95% CI 2.1-8.4, P<0.0001). CONCLUSIONMost pts achieved durable CLL disease control with 1L targeted treatments, and early PD occurs much less frequently than previously reported with CIT. However, among pts who receive 1L targeted therapies for CLL, PD within 36 months is associated with a ~4-fold higher risk of death. These results, if validated in larger data sets, will provide a practical measure for identifying a high-risk subgroup of pts in need of novel treatment strategies in future trials.
Pirtobrutinib versus usual care for patients with richter transformation of chronic lymphocytic leukemia: Inverse probability of treatment weighting-based analysis of BRUIN trial and mayo observational cohort
Hampel, Paul J. , Schwager, Susan M., Hanson, Curtis A. , King, Rebecca, Zepeda, Cinthya Mendoza, Koehler, Amber B. , Behnken, Amy, Coddington, Catherine, Wang, Yucai , Rabe, Kari G. , Roeker, Lindsey E. , Zhou, Jihao , Atallah‐Yunes, Suheil Albert , Shi, Min , Kenderian, Saad S. , Muchtar, Eli , Kay, Neil E. , Coddington, Catherine, Slager, Susan L. , Parikh, Sameer A.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5673-5673

10.1182/blood-2025-5673 Get It

Abstract Introduction: Pirtobrutinib, a highly selective non-covalent BTK inhibitor, demonstrated encouraging efficacy in Richter transformation (RT) of chronic lymphocytic leukemia (CLL) in the BRUIN trial (Wierda et al, Lancet Haematology, 2024). However, a control arm was not included in this phase 1/2 trial, and how pirtobrutinib compares to usual care is unknown. To address this gap of knowledge, we sought to compare efficacy outcomes in BRUIN to that in a control cohort consisting of RT patients treated with usual care at Mayo Clinic. Methods: The study was approved by the Mayo Clinic IRB. Patient-level data from BRUIN (n=79; investigator-assessed) were obtained from the study sponsor. Patients with histologically confirmed RT (large B-cell lymphoma) who received at least one line of therapy (n=230) were identified from the Mayo Clinic CLL Database. Multivariable logistic regression was employed to calculate propensity scores for baseline covariates (ie, age at RT treatment line, number of prior lines of CLL treatment [truncated at 3], number of prior lines of RT treatment [truncated at 3], and LDH). For each Mayo patient, propensity scores for each line of RT therapy were calculated, and the line with the highest propensity score was chosen as the index RT treatment line. Using the inverse probability treatment weighting (IPTW) methodology, individual weights were computed, and standardized mean differences (SMDs) were examined for each of the unadjusted and weighted baseline covariates to ensure that balance was obtained between BRUIN cases and Mayo controls. Overall survival (OS; the primary endpoint) and progression-free survival (PFS) were analyzed using unweighted and weighted Cox proportional hazards models. Unweighted and weighted overall response rates (ORRs) and complete response (CR) rates were analyzed using logistic regression. Results: The final analysis dataset contained 79 BRUIN cases (median age 67 [range 26-95], 66% male) and 204 Mayo controls (median age 69 [range 30-89], 74% male). The BRUIN cohort had more patients with ECOG PS ≥1 (61% vs 40%, p=0.001) and elevated LDH (81% vs 63%, p=0.003) than the Mayo cohort. The proportion of patients with TP53 aberration was not statistically different in both cohorts (57% vs. 44%, p=0.15). The index line of RT treatment in the Mayo cohort included chemoimmunotherapy (n=167, 80%) and novel agent-based therapy (eg, cBTKi, venetoclax, PI3Ki, immune checkpoint inhibitor, etc; n=42, 20%). Median lines of prior CLL therapy were 2 (IQR 1-4) vs 1 (IQR 0-3) in the BRUIN and Mayo cohorts, respectively; median lines of prior RT therapy were 2 (IQR 1-2) vs 0 (IQR 0-2). The SMDs of the weighted baseline factors met pre-determined criteria (-0.25≤SMD≤0.25), indicating that balance between the two cohorts was achieved. The median follow-up was 18.3 months (range 0.7-32.9) in the BRUIN cohort and 122.8 months (range 0-280.2) in the Mayo cohort. The unweighted median OS was 12.5 months (95% CI 7.0-20.6) in the BRUIN cohort and 5.7 months (95% CI 3.9-10.7) in the Mayo cohort. The unweighted HR was 0.76 (95% CI 0.54-1.07, p=0.12). After IPTW, the weighted HR was 0.63 (95% CI 0.50-0.78, p<0.001), significantly favoring the BRUIN cohort. The unweighted median PFS was 3.6 months (95% CI 2.8-5.1) in the BRUIN cohort and 3.1 months (95% CI 2.5-4.3) in the Mayo cohort. The unweighted HR was 0.98 (95%CI 0.72-1.34, p=0.92). After IPTW, the weighted HR was 0.78 (95% CI 0.64-0.95, p=0.01), again favoring the BRUIN cohort. Response was evaluable/available in 69 patients in BRUIN and 182 patients in Mayo cohort. The unweighted ORR was 58% vs 53% in BRUIN and Mayo cohorts, respectively (OR=0.83, 95% CI 0.47-1.45, p=0.51), and the CR rate was 16% vs 36% (OR=2.94, 95% CI 1.43-5.88, p=0.003). After IPTW, the weighted OR was 0.65 (95% CI 0.45-0.93, p=0.02) for ORR, favoring the BRUIN cohort, and 1.89 (95%CI 1.23-2.86, p=0.02) for CR rate, favoring the Mayo cohort. Conclusions: This individual patient-level IPTW-based analysis demonstrated that single agent pirtobrutinib is associated with improved OS, PFS, and ORR compared to usual care in patients with RT. These results support the choice of pirtobrutinib over traditional therapies for RT. Although these results are encouraging, the durability of response to pirtobrutinib remains suboptimal. Ongoing trials and other future research will evaluate the efficacy of pirtobrutinib in combination with other treatments in this setting.
AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning
Corraes, Andre De Menezes Silva , Shaw, Monica , Holmes, Lucy , Burgstahler, Allison, Riester, Kimberly, Jankowski, Matthew, Hampel, Paul J. , Kapoor, Prashant , Khurana, Arushi , Kourelis, Taxiarchis , Leung, Nelson , Warsame, Rahma , Kumar, Shaji , Ansell, Stephen M. , Johnston, Patrick B. , Guzman, Emmanuel Contreras , Shaw, Monica, Holmes, Lucy, Burgstahler, Allison, Mclean, Jody, Villasboas, José C. , Bennani, N. Nora , Binder, Moritz , Gertz, Morie A. , Kenderian, Saad S. , Cook, Joselle , Shah, Meera , Alkhateeb, Hassan B. , Wang, Yucai , Durani, Urshila , Paludo, Jonas , Lin, Yi

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6131-6131

10.1182/blood-2025-6131 Get It

Abstract Introduction: CAR-T therapy has transformed cancer therapy. with its first Food and Drug Administration (FDA) approved product in August 2017. Given the expanding indications and growing experience, particularly with management of immediate toxicities requiring specialized expertise such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity syndrome (ICANS), FDA recently removed the Risk Evaluation and Mitigation Strategies (REMS) for CD19 and BCMA targeting CAR-T on June 26th2025. In particular, given that CRS and ICANS typically occur in the first 2 weeks post CAR-T infusion, the minimum required stay near CAR-T treatment center is reduced from one month to 2 weeks. While this could reduce treatment burden for patients (pts) who need to travel away from home to receive CAR-T, there is a need to update the transition of care from CAR-T center to pts' local oncology practice. Pts carry in their rate of recovery and have varying supportive care needs in the second half of the month post CAR-T infusion. To assist with care transition and planning, we examine the use of AI multimodal large language model (LLM) to predict patients' supportive care needs 2 weeks after CAR-T infusion based on the clinical data at the time of CAR-T evaluation, prior to leukapheresis. This timepoint was selected to also maximize travel, lodging and caregiver planning for pts and family as well. Methodology: Pts who were treated with FDA-approved CAR-T at Mayo Clinic Rochester between December 2022 and June 2025 were examined. Based on experiences with referral practices in the Midwest region, we defined patients with high monitoring needs as those who between day 14-30 post CAR-T had either hospital admission due to recurrent CRS or ICANS or required transfusion of more than 1 blood product per week (red blood cell or platelets). Others were classified as low monitoring needs. Clinical notes, labs, vital signs and electrocardiogram at the time of CAR-T evaluation were abstracted and summarized by Gemini LLM for association with patients with high versus low monitoring needs post CAR-T. Model was developed and tested for predicted needs and concordance with actual outcome of these pts. Results: Among the 362 pts who received FDA approved CAR-T in the timeframe, 84 pts had high monitoring needs. An additional 84 pts with low monitoring needs were randomly selected from 278 pts. These were divided into a training cohort and test cohort of 84 pts each, with 42 pts with high and 42 pts with low monitoring needs. Demographics of the two cohorts displayed no statistical difference. LLM analysis of the clinical data at the time of CAR-T eval identified 5 categories associated with risk for high monitoring needs: 1) Disease status (clinical notes about bulky, progressive disease or CNS involvement); 2) inflammatory and tumor burden markers (CRP, LDH); 3) hematologic status (platelet, plt; neutrophil count ANC); 4) renal function; 5) performance status. Using common clinical lab parameter convention (platelets <100, ANC< 1, CrCl< 30ml/min), and prioritizing for not missing pts with high monitoring needs, LLM model was defined to predict patients for high monitoring needs if high risk feature was identified in category 1 or any category combinations; whereas patients with no high risk feature or only 1 category that is not disease status was predicted as low monitoring needs. In this model, the sensitivity was 85.7%, specificity 23.8%, F1 score 65.5%. Applying this model to test cohort 2, the sensitivity was 83.3%, specificity 28.6%, and F1 score 65.4%. Discussion: We demonstrate proof-of-concept that LLM can be used to analyze clinical data at the time of evaluation for CAR-T eligibility to predict for supportive care needs post treatment. Not surprisingly, features identified by LLM to be associated with high monitoring needs are those previously reported by us and others at the time of CAR-T evaluation and or pre-lymphodepletion to be associated with risk for cytopenia, infection, hospitalization and non-relapse mortality. Based on the summary output generated by LLM, additional opportunities for classification methods were identified to improve specificity and balanced accuracy of the LLM model. This is a promising tool for further development to assist clinicians and patients to plan their treatment journey.